Investor Overview

Corporate Profile

AtriCure was formed by a team with extensive experience in the medical device industry. The company is focused on developing innovative products using proprietary technology that provides doctors alternative, expedient methods to ablate tissue during surgical procedures.

Stock Quote

ATRC (Common)
PriceChange% ChangeVolume
$22.94 + 0.351.55%216,138
Previous CloseToday's OpenIntraday HighIntraday Low
$22.59$22.55$23.03$22.18
Exchange: NASDAQ (US Dollar)
05/29/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Reports

Date
04/10/15
Download Documentation 2014 Annual Report
03/24/15
Download Documentation AtriCure Analyst Day Presentation
02/27/15
Download Documentation Investor Presentation
02/23/15
Download Documentation Q4 Earnings Call Transcript

All Recent News

DateTitle 
04/29/15AtriCure Reports First Quarter 2015 Financial Results and Updates 2015 Outlook
Revenue of $29.9 million – up 20.3% as reported, 24% constant currency U.S. sales of $22.9 million – up 26.3% International sales of $7.0 million – up 3.9% as reported, 17.6% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 29, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, ... 
Printer Friendly Version
04/21/15AtriClip System Surpasses 50,000 Units Sold Worldwide
AtriClip is the most widely used device globally for left atrial appendage management WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 21, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold more than 50,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, making it not only the preferred surgi... 
Printer Friendly Version
04/08/15AtriCure to Announce First Quarter 2015 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 8, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, will release its financial results for the first quarter of 2015 on Wednesday, April 29, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, April 29, 2015 to discuss its first quarter 2015 financial resul... 
Printer Friendly Version
04/07/15AATS Graham Foundation and AtriCure Announce James L. Cox Fellowship in Atrial Fibrillation Surgery
Fellowship provides newly graduated cardiothoracic surgeons with a unique opportunity to be trained by nationally recognized experts in atrial fibrillation surgery WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 7, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management, together with the American Association for Thoracic Surgery ... 
Printer Friendly Version
  More News >>

National Recent News

DateTitle 
04/29/15AtriCure Reports First Quarter 2015 Financial Results and Updates 2015 Outlook
Revenue of $29.9 million – up 20.3% as reported, 24% constant currency U.S. sales of $22.9 million – up 26.3% International sales of $7.0 million – up 3.9% as reported, 17.6% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 29, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, ... 
Printer Friendly Version
04/21/15AtriClip System Surpasses 50,000 Units Sold Worldwide
AtriClip is the most widely used device globally for left atrial appendage management WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 21, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold more than 50,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, making it not only the preferred surgi... 
Printer Friendly Version
04/08/15AtriCure to Announce First Quarter 2015 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 8, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, will release its financial results for the first quarter of 2015 on Wednesday, April 29, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, April 29, 2015 to discuss its first quarter 2015 financial resul... 
Printer Friendly Version
04/07/15AATS Graham Foundation and AtriCure Announce James L. Cox Fellowship in Atrial Fibrillation Surgery
Fellowship provides newly graduated cardiothoracic surgeons with a unique opportunity to be trained by nationally recognized experts in atrial fibrillation surgery WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 7, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management, together with the American Association for Thoracic Surgery ... 
Printer Friendly Version
  More National News >>

International Recent News

DateTitle 
10/01/13In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe
AMSTERDAM, Netherlands--(BUSINESS WIRE)--Oct. 1, 2013-- AtriCure, Inc. (Nasdaq: ATRC), is partnering with leading atrial fibrillation (Afib) centers and thought leaders across Europe to provide best-in-class training on surgical ablation. The launch of an international Maze IV Training program will take place on October 1 in Germany at Sana Stuttgart Cardiac Surgery Center, one of six initial European hospitals selected to participate in th... 
Printer Friendly Version
06/18/13Promising Mid-Term Results From Thoracoscopic Ablation of Persistent Atrial Fibrillation Presented at Meeting of International Society for Minimally Invasive Cardiothoracic Surgery
Patients show three-year freedom from atrial fibrillation, anti-arrhythmic drugs PRAGUE--(BUSINESS WIRE)--Jun. 18, 2013-- A leading German cardiovascular heart center reported promising mid-term results for the surgical treatment of persistent atrial fibrillation (Afib) during last week’s International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) meeting being held in Prague, Czech Republic. At three-year follow-up, 80 percen... 
Printer Friendly Version
  More International News >>

Company Calendar

There are currently no events scheduled.
  More Events >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.